Patents by Inventor Magnus Dahlbäck

Magnus Dahlbäck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
    Patent number: 6932962
    Abstract: Aerosol formulations suitable for use in pressurised metered dose inhalers comprise a hydrofluoroalkane propellant, an medicament for inhalation and a surfactant which is a a C8–C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide.
    Type: Grant
    Filed: December 19, 1995
    Date of Patent: August 23, 2005
    Assignee: AstraZeneca AB
    Inventors: Kjell Bäckström, Magnus Dahlbäck, Ann Johansson, Göran Källstrand, Elisabet Lindqvist
  • Aerosol formulations of peptides and proteins
    Patent number: 6524557
    Abstract: A pharmaceutical aerosol formulation comprising (a) a HFA propellant; (b) a pharmaceutically active polypeptide dispersible in the propellant; and (c) a surfactant which is a C8-C16 fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide, which surfactant enhances the systemic absorption of the polypeptide in the lower respiratory tract. The invention also relates to methods of manufacturing such formulations and the use of such formulations in treating patients.
    Type: Grant
    Filed: April 5, 1996
    Date of Patent: February 25, 2003
    Assignee: AstraZeneca AB
    Inventors: Kjell Bäckström, Magnus Dahlbäck, Ann Johansson, Göran Källstrand, Elisabet Lindqvist
  • Therapeutic preparations for inhalation
    Patent number: 6436902
    Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mamnmalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: August 20, 2002
    Assignee: AstraZeneca AB
    Inventors: Kjell Bäckström, Björn Wallmark, Magnus Dahlbäck, Peter Edman, Ann Johansson